Overview
Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies
Status:
Recruiting
Recruiting
Trial end date:
2023-12-01
2023-12-01
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
The purpose of this clinical trial is to evaluate the effectiveness and safety of oncolytic viruses H101 intra-tumor injection combined with or without radiotherapy in refractory or recurrent gynecological malignancies. And further research the mechanism of oncolytic viruses H101.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Liu Zi
Criteria
Inclusion Criteria:- Written informed consent obtained.
- Age ≥ 18 years at the time of study entry.
- Histological or Cytologically diagnosed gynecological malignancies.
- Failure to prior standard treatment (surgery, chemotherapy, radiotherapy);
- Refractory/recurrence/metastasis gynecological cancer
- At least one measurable lesion according to the RECIST1.1.
- Cooperative Oncology Group-Status (ECOG Status) 0-3.
- The last treatment should be over 2 weeks.
Exclusion Criteria:
- History or evidence of active autoimmune disease that requires systemic treatment.
- Participated in other anti-tumor clinical trials within 4 weeks.
- Patients who have a contraindication to similar drugs.
- That failure to follow up regularly.